Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 25, 2006
Epidemiology of nasopharyngeal carcinoma in the United States: improved survival of Chinese patients within the keratinizing squamous cell carcinoma histologyS-H I Ou, J A Zell, A Ziogas, et al.
Clinical Genetics|April 23, 2014
Innovative personalized medicine in gastric cancer: time to move forwardJ Lee, K-M Kim, W K Kang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 13, 2006
Long-term survival differences for bronchiolo-alveolar carcinoma patients with ipsilateral intrapulmonary metastasis at diagnosisJ A Zell, S-H I Ou, A Ziogas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 31, 2014
Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLCS-H I Ou, P A Jänne, C H Bartlett, et al.
Lung Cancer (Amsterdam, Netherlands)|August 26, 2017
Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinibA Oztan, S Fischer, A B Schrock, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 19, 2020
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX studyT Mok, D R Camidge, S M Gadgeel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 14, 2019
Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001A T Shaw, G J Riely, Y-J Bang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2013
The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinomaH R Kim, S M Lim, H J Kim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 2, 2020
Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancerJ J Lin, S V Liu, C E McCoach, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 18, 2016
What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)A Drilon, G Li, S Dogan, et al.
Pageof 2